| Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques (NCT04417803) | Centre Hospitalier Universitaire Dijon | 2021-05-17 |
| A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed (NCT03128164) | Hutchison Medipharma Limited | 2017-08-08 |
| tTF-NGR Phase I Study (NCT02902237) | University Hospital Muenster | 2017-03-01 |
| Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas (NCT02740270) | Novartis Pharmaceuticals | 2016-07-22 |
| Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT (NCT02786485) | Bellicum Pharmaceuticals | 2016-05-01 |
| Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas (NCT02661542) | Fujifilm Pharmaceuticals U.S.A., Inc. | 2016-01-01 |
| Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors (NCT02211755) | National Cancer Institute (NCI) | 2014-10-06 |
| Nonmyeloablative Haploidentical Transplant Followed by MLN9708 (NCT02169791) | Northside Hospital, Inc. | 2014-07-15 |
| A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001 (NCT02096341) | EpicentRx, Inc. | 2014-04-01 |
| CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) (NCT02274584) | Peking University | 2014-03-01 |
| Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation. (NCT02452099) | Maria Sklodowska-Curie National Research Institute of Oncology | 2014-01-01 |
| Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas (NCT01828008) | Han weidong | 2013-04-01 |
| Bronchoscopic Sampling Techniques in Sarcoidosis (NCT01836822) | Medical University of Warsaw | 2013-03-01 |
| Virtual Bronchoscopy (VB) vs. Endobronchial Ultrasound (EBUS) Guided Mediastinal Sampling (NCT01784185) | Medical University of Warsaw | 2013-01-01 |
| Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas (NCT01490047) | Ludwig Institute for Cancer Research | 2013-01-01 |
| A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas (NCT02048488) | Tesaro, Inc. | 2012-10-01 |
| A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas (NCT01512758) | Millennium Pharmaceuticals, Inc. | 2012-02-06 |
| A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma. (NCT01237236) | Novartis Pharmaceuticals | 2010-12-21 |
| A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval (NCT01525394) | Eisai Inc. | 2010-12-01 |
| Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting (NCT01387841) | Bharath Charitable Cancer Hospital and Institute | 2010-05-01 |
| Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing (NCT01031641) | National Cancer Institute (NCI) | 2009-11-19 |
| Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology (NCT02140736) | Hospira, now a wholly owned subsidiary of Pfizer | 2009-09-01 |
| T-cell Depleted Alternative Donor Transplantation (NCT00968864) | Wake Forest University Health Sciences | 2009-08-01 |
| A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies. (NCT02578316) | Eisai Inc. | 2009-06-01 |
| Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy (NCT00796562) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2008-12-01 |
| Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma (NCT00947739) | New Mexico Cancer Research Alliance | 2008-09-01 |
| A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma (NCT00725634) | AVEO Pharmaceuticals, Inc. | 2008-09-01 |
| Assess the Oral Bioavailability of New ABT-263 Formulations (NCT00743028) | Abbott | 2008-08-01 |
| Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas (NCT00592163) | Alaunos Therapeutics | 2007-12-01 |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas (NCT00553189) | National Cancer Institute (NCI) | 2007-08-09 |
| Collection of Tissue Samples for Cancer Research (NCT00900198) | National Cancer Institute (NCI) | 2006-07-06 |
| Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma (NCT00396864) | Celgene | 2006-05-01 |
| Trial of Two Schedules of Perifosine for Patients With Solid Tumors or Lymphomas (NCT00389077) | AEterna Zentaris | 2005-01-01 |
| Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy (NCT00222443) | University of Oklahoma | 2004-09-01 |
| Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies (NCT00513318) | University of California, San Francisco | 2004-08-01 |
| Post Transplant Donor Lymphocyte Infusion (NCT00167180) | Masonic Cancer Center, University of Minnesota | 2004-01-01 |
| Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas (NCT00152126) | St. Jude Children's Research Hospital | 2003-08-01 |
| Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas (NCT00023166) | Enzon Pharmaceuticals, Inc. | 2001-05-01 |
| Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer (NCT00006518) | National Cancer Institute (NCI) | 2000-12-06 |
| Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant (NCT01200017) | Christopher Dvorak | |
| Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours (NCT01194193) | AstraZeneca | |